CO2021007647A2 - Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos - Google Patents
Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismosInfo
- Publication number
- CO2021007647A2 CO2021007647A2 CONC2021/0007647A CO2021007647A CO2021007647A2 CO 2021007647 A2 CO2021007647 A2 CO 2021007647A2 CO 2021007647 A CO2021007647 A CO 2021007647A CO 2021007647 A2 CO2021007647 A2 CO 2021007647A2
- Authority
- CO
- Colombia
- Prior art keywords
- nanoemulsification
- production methods
- cannabis oil
- oil powder
- powder formulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL261132A IL261132A (en) | 2018-08-13 | 2018-08-13 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
| PCT/IL2019/050268 WO2020035850A1 (en) | 2018-08-13 | 2019-03-11 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021007647A2 true CO2021007647A2 (es) | 2021-08-30 |
Family
ID=63998426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0007647A CO2021007647A2 (es) | 2018-08-13 | 2021-06-10 | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11712430B2 (https=) |
| EP (1) | EP3716946A1 (https=) |
| JP (1) | JP2021535935A (https=) |
| CN (1) | CN113473965A (https=) |
| AU (1) | AU2019322212B2 (https=) |
| BR (1) | BR112021009869A2 (https=) |
| CO (1) | CO2021007647A2 (https=) |
| IL (2) | IL261132A (https=) |
| WO (1) | WO2020035850A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3138630A1 (en) * | 2019-05-02 | 2020-11-05 | Betterlife Pharma Inc. | Cannabinoid stock transdermal formulations |
| US10780075B1 (en) | 2019-07-31 | 2020-09-22 | Etain IP, LLC | Water soluble cannabis composition |
| CN114245739A (zh) * | 2019-08-12 | 2022-03-25 | 腾思凯真私人有限公司 | 大麻二酚口腔崩解片 |
| KR20230047095A (ko) | 2020-07-29 | 2023-04-06 | 카낙 테크놀로지스, 엘엘씨 | 치료용 친유성 활성물질의 개선된 전달을 위한 약제학적 조성물 |
| KR20220128405A (ko) * | 2020-07-29 | 2022-09-20 | 카낙 테크놀로지스, 엘엘씨 | 화장용 사용을 위한 친지성 물질의 개선된 포뮬레이션 |
| IL293086A (en) | 2020-07-29 | 2022-07-01 | Karnak Tech Llc | Formulations of orally administered lipophilic dietary supplements and beneficial oils |
| CA3188864A1 (en) * | 2020-08-14 | 2022-02-17 | Ori LIEBERMAN | Dosing capsule made from cannabis-derived resin and methods of making the same |
| CA3114085A1 (en) * | 2021-04-05 | 2022-10-05 | MEC11S Inc. | Composition comprising cannabis extracts and method of manufacturing same |
| JP2023010676A (ja) * | 2021-07-09 | 2023-01-20 | 株式会社東洋新薬 | 固形組成物 |
| AU2024305502A1 (en) | 2023-06-16 | 2026-01-08 | Pico Ip, Llc | A process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
| WO2026037496A1 (en) * | 2024-08-14 | 2026-02-19 | Tetra Pharm Technologies | A self-emulsifying solid composition comprising a cannabinoid |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013518097A (ja) * | 2010-01-26 | 2013-05-20 | イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー | 肺高血圧を予防および治療するための組成物および方法 |
| US8629177B2 (en) * | 2010-08-24 | 2014-01-14 | Aphios Corporation | Nanoencapsulated delta-9-tetrahydrocannabinol |
| ES2739194T3 (es) | 2012-01-19 | 2020-01-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulación y método para aumentar la biodisponibilidad oral de fármacos |
| JP6247685B2 (ja) | 2012-05-16 | 2017-12-13 | メワ・シン | 実質的に水不溶性の薬物の送達のための医薬組成物 |
| WO2015171445A1 (en) | 2014-05-06 | 2015-11-12 | Mewa Singh | Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation |
| US20160058866A1 (en) | 2014-09-02 | 2016-03-03 | Ronald D. Sekura | Alternative solutions for the administration of cannabis derived botanical products |
| US9629886B2 (en) | 2015-02-24 | 2017-04-25 | Ers Holdings, Llc | Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil |
| WO2016147186A1 (en) | 2015-03-19 | 2016-09-22 | One World Cannabis Ltd | Preparations of cannabis emulsions and methods thereof |
| CA2986268C (en) * | 2015-05-28 | 2024-01-02 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| BR102015024165A2 (pt) * | 2015-09-18 | 2017-03-28 | Prati Donaduzzi & Cia Ltda | composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso |
| AU2016347651A1 (en) * | 2015-10-26 | 2018-05-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Novel cannabinoid formulations |
| JP2019511580A (ja) | 2016-04-15 | 2019-04-25 | エスアールイー ウェルネス インク．Ｓｒｅ Ｗｅｌｌｎｅｓｓ Ｉｎｃ． | 乳化剤を使用して大麻油を親水性にする方法及び関連するカンナビノイド組成物 |
| JP2020514282A (ja) * | 2016-12-20 | 2020-05-21 | ティルレイ，インコーポレイティド | 新規カンナビノイド組成物および使用方法 |
| CO2017007962A1 (es) * | 2017-08-04 | 2018-04-19 | Alsec Alimentos Secos S A S | Nanoparticulas oleosas de cannabis microencapsuladas en polvo |
-
2018
- 2018-08-13 IL IL261132A patent/IL261132A/en unknown
-
2019
- 2019-03-11 EP EP19714807.5A patent/EP3716946A1/en not_active Withdrawn
- 2019-03-11 WO PCT/IL2019/050268 patent/WO2020035850A1/en not_active Ceased
- 2019-03-11 JP JP2021547984A patent/JP2021535935A/ja active Pending
- 2019-03-11 BR BR112021009869A patent/BR112021009869A2/pt not_active Application Discontinuation
- 2019-03-11 AU AU2019322212A patent/AU2019322212B2/en active Active
- 2019-03-11 US US16/958,341 patent/US11712430B2/en active Active
- 2019-03-11 CN CN201980067584.5A patent/CN113473965A/zh active Pending
-
2020
- 2020-06-17 IL IL275430A patent/IL275430A/en unknown
-
2021
- 2021-06-10 CO CONC2021/0007647A patent/CO2021007647A2/es unknown
-
2023
- 2023-06-14 US US18/209,954 patent/US20230321031A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11712430B2 (en) | 2023-08-01 |
| CA3086887A1 (en) | 2020-02-20 |
| AU2019322212B2 (en) | 2022-09-29 |
| AU2019322212A1 (en) | 2021-04-08 |
| IL275430A (en) | 2020-08-31 |
| CN113473965A (zh) | 2021-10-01 |
| JP2021535935A (ja) | 2021-12-23 |
| EP3716946A1 (en) | 2020-10-07 |
| IL261132A (en) | 2018-11-04 |
| US20210059975A1 (en) | 2021-03-04 |
| BR112021009869A2 (pt) | 2022-05-17 |
| US20230321031A1 (en) | 2023-10-12 |
| WO2020035850A1 (en) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021007647A2 (es) | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos | |
| CR20210483A (es) | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos | |
| CL2017001893A1 (es) | Uso de prg4 como agente antiinflamatorio | |
| CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
| CL2018003432A1 (es) | Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales. | |
| PE20200726A1 (es) | Composicion de cannabis | |
| MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
| MX370963B (es) | Composiciones para el cuidado personal. | |
| BR112019000130A2 (pt) | formulação agrícola, formulação aquosa compreendendo a mesma, agente de tratamento agrícola, produto vegetal, método de tratamento de um alvo agrícola e método para reduzir a transmissão de uma doença fúngica de planta | |
| WO2015089419A3 (en) | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components | |
| EP4653048A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
| CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
| HRP20201333T1 (hr) | Kompozicija koja sadrži oleosome sa različitom raspodjelom veličina | |
| MX2019009783A (es) | Metodo para fabricar una barra que comprende antitranspirante. | |
| AR085527A1 (es) | Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida | |
| CO2020013182A2 (es) | Método y composición para el tratamiento de trastornos del snc | |
| MX2017004998A (es) | Composicion que contiene un extracto o fraccion de una planta del genero justicia. | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| MX2019007614A (es) | Nanoparticulas para su uso para tratar un trastorno neuronal. | |
| AR075686A1 (es) | Nanoparticulas de policosanol | |
| CO2017007962A1 (es) | Nanoparticulas oleosas de cannabis microencapsuladas en polvo | |
| MX375799B (es) | Preparación de absorbedores de uv de tamaño nanométrico. | |
| MX2016007803A (es) | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. | |
| IT201700067430A1 (it) | Nanoparticelle quali veicoli di rilascio di principi attivi e metodi per la loro produzione |